A chemical quenching- and physical blocking-based method to minimize process-mediated aggregation of antibody-crosslinked nanoparticles for imaging application.

Critical limitation of nanoparticles (NP) is their aggregation after functionalisation and antibody cross-linking. We analysed the cause of this aggregation with respect to functionalities (carboxyls and amines) on the NP surface. We have devised a low cost novel method to reduce such aggregations during protein cross-linking and validated it by probing the platelet surface with platelet surface-specific anti-CD41 antibody conjugated NPs.